Indian Generic Firms Eye $30Bn In Lost U.S. Drug Patents
This article was originally published in PharmAsia News
Executive Summary
More drugs losing U.S. patent protection means continued stronger growth for Indian generic firms over the next two to three years.
More drugs losing U.S. patent protection means continued stronger growth for Indian drug makers, primarily generic firms, over the next two to three years, according to a credit rating agency. The Investment Information Credit Ratings Agency estimated that branded drugs with a value of as much as $30 billion are expected to lose patent protection during that period. ICRA attributed part of the increased opportunities to Indian generic makers pursuing more complex molecules that can compete with products from major global generic manufacturers. (Click here for more
)
"Generic Opportunities To Drive Indian Pharma Sector Growth" - Business Standard (India) (8/19/2014)